REVEAL GENOMICS, S.L., a biotechnology company advancing precision oncology through biomarker innovation, today announced the presentation of four independent studies at the 2025 ASCO Annual Meeting.

Global pharma major Lupin Limited (Lupin) will present data from its Phase 1a clinical trial evaluating LNP7457, a PRMT5 ...

Welcome to The Pharma Letter ’s real-time coverage of the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, ...

Equity Insider News Commentary – With early onset cancer rates on the rise and funding being cut to NIH, the future for ...

Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the company will present the ...

Phase 2 survival and clinical benefit data meet or exceed outcomes of FDA-approved therapies in comparable metastatic breast ...

The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting is scheduled to take place in Chicago, Illinois, USA from May 30 to June 3. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990 ...

Detailed price information for Guardant Health Inc (GH-Q) from The Globe and Mail including charting and trades.

Volastra Therapeutics, a clinical-stage cancer biotechnology company focused on chromosomal instability, today announced preliminary safety and efficacy data from its ongoing, first-in-human Phase ...

Clinical validation of the Azymetric platform is demonstrated by the accelerated approval our partner Jazz Pharmaceuticals received from the U.S. Food and Drug Administration in 2024 for Ziihera® ...

GI Symposium data underscores pelareorep's clinical benefit in anal and pancreatic cancers Pelareorep featured in Key Opinion ...

Operator: Good afternoon, and welcome to Oncolytics Biotech First Quarter Conference Call. All participants are in a listen-only mode.